Drug Profile

ARGX 220

Alternative Names: ARGX-220

Latest Information Update: 05 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator argenx
Class Antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Autoimmune disorders

Most Recent Events

05 Mar 2024 ARGX 220 is available for licensing as of 05 Mar 2024. https://www.argenx.com/innovation#antibody-engineering (argenx pipeline, March 2024)
29 Feb 2024 argenx plans to submit investigational new drug (IND) application in Autoimmune disorders by end of 2025
28 Feb 2023 Preclinical trials in Autoimmune disorders in Netherlands (Parenteral) prior to February 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com